NCT02862067

SGLT2 Inhibition in Diabetes and Heart Failure

SGLT2 Inhibition in Diabetic Patients With Heart Failure With Reduced Ejection Fraction

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 18 (actual)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness in patients with systolic heart failure.

Detailed description

The investigators hypothesize that Sodium-GLucose coTransporters (SGLT)-2 inhibition will improve cardio-respiratory fitness (CRF) in patients with systolic heart failure. Participants treated with SGLT2 inhibitor Empagliflozin as standard of care will undergo assessments described below. The investigators will measure CRF with a validated cardiopulmonary exercise test at baseline and after 4 weeks of treatment received as standard of care, to determine whether SGLT2 inhibition improves cardio-respiratory fitness assessed by changes in peak oxygen consumption (VO2)(mL/kg/min) and minute ventilation (VE)/carbon dioxide production (VCO2) slope, powerful independent clinical predictors of mortality in HF.

Conditions

• Diabetes Mellitus, Type 2
• Heart Failure, Systolic

Interventions

Type	Name	Description
OTHER	Assessment of cardiorespiratory fitness	Assessment of cardiorespiratory fitness

Timeline

• Start date: 2016-07-01
• Primary completion: 2018-01-16
• Completion: 2018-01-16
• First posted: 2016-08-10
• Last updated: 2018-07-16

Locations

1 site across 1 country: United States